Stoke Therapeutics, Inc.
Stoke Therapeutics, Inc. is a U.S.-based biopharmaceutical company focused on developing RNA-targeted medicines for severe genetic diseases. Its pipeline includes zorevunersen (STK-001) for Dravet syndrome, STK-002 for autosomal dominant optic atrophy, and additional product candidates developed through its TANGO platform and collaboration structure.
Fiscal year 2025 · change from previous year
Development 2020–2025
Business
Share of revenueDrug candidates in human clinical development, including zorevunersen and STK-002.
Revenue earned from licensing IP and performing partnered development activities.
Customers
Stoke’s direct commercial customers are not yet established because its products are still in development; instead, revenue currently comes from collaboration partners such as Biogen and Acadia. If approved, its medicines would be prescribed by healthcare providers and reimbursed by third-party payors, with access shaped by specialty neurology and rare-disease treatment pathways.
Biogen and Acadia fund, develop, and potentially commercialize selected programs under alliance terms.
Physicians treating Dravet syndrome or other rare genetic disorders who would prescribe approved products.
Commercial and government payors that would influence access, reimbursement, and uptake.
Patients with severe genetic disorders who are the intended beneficiaries of the therapies.
Strategy
Stoke’s strategy centers on advancing its RNA-targeted rare-disease pipeline through clinical development and regulatory milestones. It also uses alliances to share development and commercialization responsibilities, especially outside North America, while preserving flexibility to build its own sales capability if products are approved.
It is the company’s most advanced and strategically important program.
Broader pipeline success reduces dependence on a single lead program.
Alliances extend geographic reach and reduce the need for a large internal sales force.
Geography
Stoke is headquartered in the United States and conducts its core research and development activities from there. Its commercial footprint is expected to be split between North America and ex-North America through partnerships, with Biogen covering development and commercialization outside North America for zorevunersen.
Risks
Stoke is an early-stage biotechnology company, so its value depends heavily on successful clinical development, regulatory approval, and eventual commercialization of a small number of programs. It also faces financing, partnership execution, intellectual property, and healthcare reimbursement risks that are typical for rare-disease drug developers but especially important given its limited operating history.
- Clinical development failureImpact: CriticalLikelihood: Medium
Lead programs may not show sufficient safety or efficacy in later-stage trials.
Exposure - Regulatory approval riskImpact: HighLikelihood: Medium
FDA or foreign regulators may delay, restrict, or deny approval.
Exposure: All product candidates
- Partner commercialization riskImpact: HighLikelihood: Medium
Biogen, Acadia, or future partners may not devote enough resources to launch and marketing.
Exposure: Ex-North America and partnered programs
- Financing and dilution riskImpact: HighLikelihood: Medium
The company expects to need additional capital to fund development and operations.
Exposure: Corporate funding
- Intellectual property riskImpact: MediumLikelihood: Medium
Protection of RNA platform and product rights is essential to commercialization value.
Exposure - Healthcare compliance riskImpact: MediumLikelihood: Low
Future sales and distribution arrangements must comply with anti-kickback and fraud laws.
Exposure: U.S. commercialization
Accounting
Judgemental itemsRevenue depends on timing of performance obligations under Acadia and Biogen agreements.
Impact: Can create large quarter-to-quarter swings in reported revenue
R&D accruals and trial-related expenses depend on estimates of work performed and vendor billing.
Impact: Affects operating expense timing and comparability
Equity awards are a recurring non-cash expense for a development-stage biotech.
Impact: Influences reported operating loss and dilution analysis
Pipeline assets, licenses, and other intangibles may require fair value or impairment assessments.
Impact: Could affect future earnings if asset values change
Similar listed companies
Publicly listed companies with a comparable business focus.
Spruce Biosciences, Inc
SPRB · Pharmaceutical Preparations
Neurogene Inc.
NGNE · Pharmaceutical Preparations
Biogen Inc
BIIB · Biological Products, (No Diagnostic Substances)
Biogen is a U.S.-based biopharmaceutical company built around therapies for serious neurological, immunological and rare diseases.
Arrowhead Pharmaceuticals, Inc
ARWR · Pharmaceutical Preparations
Arrowhead Pharmaceuticals is a U.S.-based biopharmaceutical company focused on developing RNA interference medicines that silence disease-causing genes.
Spero Therapeutics, Inc.
SPRO · Pharmaceutical Preparations
Gain Therapeutics, Inc.
GANX · Pharmaceutical Preparations
Last updated: 24/09/2026